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A B S T R A C T
The proteome of the DAOY medulloblastoma cell line has been investigated by an LC–MS top-down
platform. This approach, unlike bottom-up ones, allows identifying proteins and peptides in their intact/
native forms, disclosing post-translational modiﬁcations, proteoforms and naturally occurring peptides.
Indeed, 25 out of the 53 proteins identiﬁed, were not previously characterized in DAOY cells. Most of
them were functionally interconnected, being mainly involved in binding, catalytic and structural
activities, and metabolic processes. The top-down approach, applied in this preliminary study, disclosed
the presence of several naturally occurring peptide fragments that characterize DAOY cells.
ã 2016 The Authors. Published by Elsevier B.V. on behalf of European Proteomics Association (EuPA). This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
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Medulloblastoma represents the most frequent malignant brain
tumor in pediatric patients, whereas it is generally less frequent in
adult. Medulloblastoma is typically located in the posterior cranial
fossa and has a neuroectodermal origin [1]. The molecular
mechanisms underlying the etiopathogenesis of the disease are
largely unknown. Different studies pursued the proteomic proﬁl-
ing of medulloblastoma through in vitro characterization of the
available cell lines, namely DAOY, D283, ONS76 and UW228 [2–8].
In particular, Peryl et al. [2] analyzed DAOYand D283 cell pellets
by two-dimensional gel electrophoresis (2-DE) coupled with
MALDI-time-of-ﬂight-MS (MALDI-TOF-MS). This approach yielded
332 proteins and particularly relevant was the detection in both
cell lines of the antiapoptotic Ded protein possibly responsible for
medulloblastoma aggressive behaviour [2].* Corresponding author at: Consiglio Nazionale delle Ricerche, Istituto di Chimica
del Riconoscimento Molecolare, c/o Istituto di Biochimica e Biochimica Clinica,
dell'Università Cattolica del Sacro Cuore, L.go F. Vito 1, Roma 00168, Italy.
E-mail address: claudia.desiderio@icrm.cnr.it (C. Desiderio).
http://dx.doi.org/10.1016/j.euprot.2016.03.015
2212-9685/ã 2016 The Authors. Published by Elsevier B.V. on behalf of European Proteom
(http://creativecommons.org/licenses/by-nc-nd/4.0/).In another study, proteomic proﬁling was used to study the
modiﬁcations of protein expression in DAOY cells overexpressing
the neurotrophin receptor TrkC [3]. TrkC signaling is involved in
regulation of cell differentiation, proliferation and survival, and
TrkC negative tumors are generally associated with a poor
prognosis. Upon induction with the TrkC ligand neurotrophin-3,
transfected cells overexpressed 13 proteins involved in tumor
proliferation, migration and invasiveness, compared to control
untransfected cells. These data possibly suggested potential targets
to be exploited to improve the response to therapy and to reduce
tumor aggressiveness [3]. The same authors described the
characterization in DAOY cells of two proteoforms of the
superoxide dismutase (Mn-SOD or SOD2) enzyme, sharing
identical sequence, but different oxidative states [4]. The tandem
MS analysis of the relative 2-DE digested spots by MALDI-TOF/TOF,
Qq-TOF and ion trap, with both CID and ETD fragmentations,
identiﬁed the presence of oxidation at Trp-186 in both forms and
additionally at His-30 and His-31 in only one of them, possibly
responsible for a decreased SOD-2 activity [4].
Recently, Cappellari et al. [5] applied a multi-disciplinary and
quantitative approach to study the expression of ecto-50NT/
CD73 ectonucleotidase, an enzyme involved in tumor malignancy,ics Association (EuPA). This is an open access article under the CC BY-NC-ND license
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cell lines. The enzyme was expressed in DAOY and ONS76 cell lines
but only weakly in the D283, suggesting its involvement in tumor
aggressiveness and poor prognosis. 2-DE/MALDI-TOF-MS was also
applied to study the proteome of DAOY, UW228 and
ONS76 medullospheres [6]. Compared with cells grown in
adherence, the DAOY and UW228 medullospheres expressed
different proteomic proﬁles with immature stem cell features.
Conversely, spheres derived from ONS76T cells, a most immature
medulloblastoma cell line, showed only quantitative variations in
protein expression levels, compared to corresponding adherent
cells. It is noteworthy to point out the identiﬁcation, in all
medullospheres, of nucleophosmin, which could plausibly be
correlated with the capacity of medulloblastoma to survive in
adverse tissue environments [6].
Recently, the proteomic characterization of exosomes released by
D283, DAOYand UW228 cellsallowed the identiﬁcationof numerous
protein species involved in cell migration and modulation of the
immune response, suggesting a possible role of extracellular vesicles
in tumor aggressiveness and progression [7]. Furthermore, SDS-
PAGE and MALDI-TOF analysis of exosomes from DAOY, UW228 and
ONS76 grown in adherence and as medullosphere, allowed the
characterization of 33 proteins, including several iron carrier
proteins, evidencing a possible role of iron in tumor aggressiveness
and proliferation [8]. More recently, a proteomic approach was
exploited to study the proteome of the Human Sonic Hedgehog
(SHH) medulloblastoma subgroup (exhibiting constitutive aberrant
activation of the SHH pathway) before and after retinoic acid-
induced differentiation [9]. The results of this study indicated that
68 proteins were differently modulated in induced-versus-control
cells, the heat shock protein 70 being overexpressed in non-induced
cells [9].
Overall, to date, all studies reporting the proteomic characteriza-
tion of medulloblastoma cell lines have been based on bottom-up
approaches, thus identifying proteins after enzymatic digestion.
The present study provides the ﬁrst attempt to investigate the
medulloblastoma DAOY cell proteome in its intact protein state,
using a top-down LC–MS proteomic strategy. This approach is
particularly suitable for the identiﬁcation of small proteins (<25
kDa) and peptides. In addition, through the analysis of naturally
occurring forms, it allows identifying PTMs, fragment peptides,
isoforms and proteoforms, that may represent key molecules
associated to the onset and progression of human disorders. The
present data could provide important contributions to the deﬁnition
of the medulloblastoma molecular signature, plausibly including
potential therapeutic targets and diagnostic biomarkers.
2. Material and methods
2.1. Reagents and chemicals
All organic solvents employed in this study were of LC–MS grade
purity. Acetonitrile (ACN), methanol, water, and formic acid (FA)
were purchased from Merck (Darmstadt, Germany). 2,2,2-triﬂuoro-
acetic acid (TFA) was purchased from Mallinckrodt Baker B.V.
(Deventer, The Netherlands). Ultrapure water for sample pretreat-
ment was obtained through the P.Nix Power System apparatus,
(Human, Seoul, Korea). The protease-inhibitor cocktail (AEBSF,
Aprotinin, Bestatin, E-64, EDTA, and Leupeptin) was purchased from
Sigma-Aldrich (Buchs, Switzerland). Media and supplements for cell
culture were purchased from Euroclone (Milan,Italy).
2.2. Instrumentation
HPLC-ESI–MS/MS top-down analyses were performed on an
UltiMate RSLCnano System (ThermoFisher Scientiﬁc, San Jose, CA,USA) coupled to Orbitrap Elite high resolution mass spectrometry
detector (ThermoFisher) with ESI source. Reverse-phase chroma-
tography was performed on 150  1.0 mm Zorbax 300 SB-C8
3.5 mm (Agilent Technologies, Santa Clara, CA, USA) columns.
2.3. Sample pretreatment
200,000 DAOY cells were plated in 6-well plates, using
complete standard growth medium (high glucose Dulbecco’s
Modiﬁed Eagle’s Medium, 1% Pen/Strep, 1% L-Glutamine, 10% Fetal
Bovine Serum). 24 h after plating the cell monolayer was washed
twice in PBS, and starved in serum-free DMEM for 24 h. Thereafter,
the cells were detached by use of trypsin and collected for
proteomic analysis. To this aim, mechanical disruption of the cell
membranes was performed after acidiﬁcation in 0.1% TFA (v/v)
solution mixed with the protease-inhibitor cocktail: cell pellets
underwent three cycles of freezing, thawing and sonication. The
resulting solution was then lyophilized, suspended in 50 mL of 0.1%
(v/v) TFA aqueous solution, and subsequently analyzed by HPLC-
ESI-Orbitrap Elite-MS.
2.4. HPLC-ESI-Orbitrap Elite-MS analysis
Top-down HPLC–MS/MS chromatographic analyses were per-
formed using an aqueous solution of FA (0.1%, v/v) as eluent A and
ACN/water mixture (80:20, v/v) 0.1% FA (v/v) as eluent B. The
following step gradient was applied: (i) from 0 to 5% of eluent B
(2 min), (ii) from 5 to 70% of eluent B (38 min), (iii) from 70% to 99%
of eluent B (5 min), (iv) 99% eluent B (6 min), at a ﬂow rate of 50 mL/
min, followed by column reconditioning, from 99 to 5% B (2 min) to
5% eluent B (10 min). In order to prevent ESI source contamination
from sample salts, MS acquisition in the positive ion mode started
4 min after sample injection. MS spectra were collected using Full
Scan acquisition mode, in the 350–2000 m/z range, with the
resolving power set to 60000. MS/MS analyses were performed in
Data-Dependent Scan (DDS) mode, by selecting and fragmenting
the ﬁve most intense multiply-charged ions of the Full Scan spectra
by Collision Induced Dissociation (CID, 35% normalized collision
energy), with a resolving power of 60000. The minimum signal
intensity required was 500.0; the isolation width was 5 m/z, default
charge state +2, activation Q 0.25 and activation time 10 ms. The
DDS set parameters were as follows: repeat count 1, repeat
duration 30 s, exclusion list size 500, exclusion duration 15 s,
exclusion mass width relative to reference mass: low 10 ppm, high
10 ppm, minimum signal threshold (counts) 500, default charge
state 2, isolation width 5 (m/z), activation Q 0.250, activation time
10 msec.
The tuning parameters of the ESI source were as follows:
capillary temperature 300 C, source voltage 4.0 kV, sheath gas 12,
auxiliary gas 0, S lens RR level 60%. The injected volume was 20 mL.
2.5. MS and MS/MS spectra data analysis
High resolution MS and MS/MS data were elaborated both
manually, using Xcalibur (version 2.0.7 SP1, Thermo Fisher
Scientiﬁc) deconvolution software, and automatically through
the Proteome Discoverer 1.4.0 software (2013, Thermo Fisher
Scientiﬁc). The analysis was performed using the SEQUEST HT
cluster search engine against the Swiss Prot Homo Sapiens
proteome (Uniprot_homo + sapiens_reviewed, released on August
2014).
The setting parameters were as follows: minimum precursor
mass 300 Da; maximum precursor mass 10000 Da; total intensity
threshold 0.0; minimum peak count 5; Signal to Noise (S/N)
threshold 3; precursor mass tolerance 10 ppm; fragment mass
tolerance 0.6 Da, use average precursor mass “false”, use average
Table 1
Proteins and peptides identiﬁed in medulloblastoma DAOY cells by top-down LC-ESI-Orbitrap Elite MS/MS proteomic analysis.
Accessiona,b Descriptiona Identiﬁcation in
medulloblastoma
cell lines
S
Coverage
#
Peptides
MW
[kDa]
P07737 Proﬁlin-1 – 89.29 6 15.0
Identiﬁed peptides MH+ [Da] RT
GTCQDAAIVGYKDSPSVWAAVPGKTFVNITPAEVGVLVGKDRSSF 4637.395 29.74
RTKSTGGAPTFNVTVTKTDKTLVLLMGKEGVHGGLINKKCYEMASHLRRSQY 5722.011 25.31
RTKSTGGAPTFNVTVTKTDKTL 2323.260 19.96
MGKEGVHGGLINKKCYEMASHLRRSQY 3092.525 20.48
GTCQDAAIVGYKDSPSVW 1896.880 24.48
YVNGLTLGGQKCSVIRDSLLQDGEFSMD 3045.466 28.10
P62937 Peptidyl-prolyl cis-trans isomerase A [6] 24.85 8 18.0
Identiﬁed peptides MH+ [Da] RT
DIAVDGEPLGRVSFE 1603.793 25.22
FDIAVDGEPLGRVSFE 1750.863 27.53
ILKHTGPGILSMANAGPNTNGSQF 2425.227 23.93
IAVDGEPLGRVSFE 1488.768 24.57
FDIAVDGEPLGRVSFEL 1863.949 30.70
VDGEPLGRVSFE 1304.649 22.63
DIAVDGEPLGRVSFEL 1716.876 28.76
AVDGEPLGRVSFE 1375.685 22.92
P60709 Actin, cytoplasmic 1 [7]d, [8], [8]d 5.33 2 41.7
Identiﬁed peptides MH+ [Da] RT
WISKQEYDESGPSIVHRKCF 2409.166 21.25
ISKQEYDESGPSIVHRKCF 2223.089 19.31
P60174 Triosephosphate isomerase [6] 15.38 2 30.8
Identiﬁed peptides MH+ [Da] RT
IGEKLDEREAGITEKVVFEQTKVIADNVKDWSKVVL 4086.217 31.71
VDIINAKQ 900.514 16.84
P09382 Galectin-1 [6]c 19.26 2 14.7
Identiﬁed peptides MH+ [Da] RT
LTVKLPDGYEFKFPNRLNL 2264.243 30.74
ITFDQANLTVKLPDGYEFKFPNRLNL 3053.624 31.12
P68104 Elongation factor 1-alpha 1 – 15.80 4 50.1
Identiﬁed peptides MH+ [Da] RT
GNVAGDSKNDPPMEAAGFTAQ 2076.929 20.63
VIILNHPGQISAGYAPVLDCHTAHIACK 2941.517 24.43
FVPISGWNGDNMLEPSANMPWFKG 2694.244 31.32
GNVAGDSKNDPPMEAAGF 1776.785 21.76
P02545 Prelamin-A/C [6]c, [3] 5.57 2 74.1
Identiﬁed peptides MH+ [Da] RT
TCGQPADKASASGSGAQVGGPISSGSSASSVTVTR 3165.505 18.59
CGTCGQPADKASASGSGAQVGGPISSGSSASSVTVTR 3325.530 18.91
P23528 Coﬁlin-1 [2] [3] 16.87 1 18.5
Identiﬁed peptides MH+ [Da] RT
VKMLPDKDCRYALYDATYETKESKKEDL 3352.641 22.07
P23527 Histone H2B type 1-O – 22.22 1 13.9
Identiﬁed peptides MH+ [Da] RT
VRLLLPGELAKHAVSEGTKAVTKYTSSK 2983.694 24.95
P62805 Histone H4 [8]d 39.81 1 11.4
Identiﬁed peptides MH+ [Da] RT
LENVIRDAVTYTEHAKRKTVTAMDVVYALKRQGRTLYGFGG 4627.456 28.39
Q9BQE3 Tubulin alpha-1C chain [2] 6.46 2 49.9
Identiﬁed peptides MH+ [Da] RT
YCLEHGIQPDGQMPSDKTIGGGDDSFNTF 3129.355 25.10
EHGIQPDGQMPSDKTIGGGDDSFNTF 2750.198 23.52
Q8NC51 Plasminogen activator inhibitor 1 RNA-binding protein – 4.66 2 44.9
Identiﬁed peptides MH+ [Da] RT
PGHLQEGFGCVVTNRF 1760.851 24.59
PGHLQEGFGCVVTNRFDQL 2117.015 26.42
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Table 1 (Continued)
Accessiona,b Descriptiona Identiﬁcation in
medulloblastoma
cell lines
S
Coverage
#
Peptides
MW
[kDa]
P10809 60 kDa heat shock protein, mitochondrial [2], [7]d, [8] 5.41 2 61.0
Identiﬁed peptides MH+ [Da] RT
VVVTEIPKEEKDPGMGAMGGMGGGMGGGMF 2926.325 26.43
EVVVTEIPKEEKDPGMGAMGGMGGGMGGGMF 3055.365 26.77
P07910 Heterogeneous nuclear ribonucleoproteins C1/C2 [2] 6.54 2 33.6
Identiﬁed peptides MH+ [Da] RT
YYDRMYSYPARVPPPPPIAR 2409.208 22.54
YSYPARVPPPPPIAR 1680.921 21.05
Q99497 Protein DJ-1 [6], [3] 12.17 1 19.9
Identiﬁed peptides MH+ [Da] RT
AIVEALNGKEVAAQVKAPLVLKD 2376.386 24.54
P27797 Calreticulin [6] 2.88 1 48.1
Identiﬁed peptides MH+ [Da] RT
WQVKSGTIFDNF 1441.711 27.75
P62158 Calmodulin – 9.40 2 16.8
Identiﬁed peptides MH+ [Da] RT
MIREADIDGDGQVN 1532.700 18.61
IREADIDGDGQVN 1401.662 17.12
P52272 Heterogeneous nuclear ribonucleoprotein M [2],[7]d 3.56 2 77.5
Identiﬁed peptides MH+ [Da] RT
QGGGGGGGSVPGIER 1284.629 16.44
VPAGMGAGLER 1057.546 18.42
Q9H1E3 Nuclear ubiquitous casein and cyclin-dependent kinase substrate 1 – 12.35 1 27.3
Identiﬁed peptides MH+ [Da] RT
KVVDYSQFQESDDADEDYGRDSGPPTKKIR 3445.618 19.23
P06733 Alpha-enolase [2], [6], [7]d 8.99 1 47.1
Identiﬁed peptides MH+ [Da] RT
LKVNQIGSVTESLQACKLAQANGWGVMVSHRSGETEDTF 4191.069 27.95
P05787 Keratin, type II cytoskeletal 8 [7]d 4.97 2 53.7
Identiﬁed peptides MH+ [Da] RT
AVVVKKIETRDGKLVSESSDVLPK 2597.487 19.69
DGKLVSESSDVLPK 1473.781 19.42
P24534 Elongation factor 1-beta – 7.11 1 24.7
Identiﬁed peptides MH+ [Da] RT
GFGDLKSPAGLQVLND 1630.844 25.38
Q01105 Protein SET [7]d 10.00 1 33.5
Identiﬁed peptides MH+ [Da] RT
FVNHPQVSALLGEEDEEALHYLTRVEVTE 3324.642 29.91
P05783 Keratin, type I cytoskeletal 18 – 7.21 1 48.0
Identiﬁed peptides MH+ [Da] RT
SLGSVQAPSYGARPVSSAASVYAGAGGSGSR 2854.400 21.50
P63241 Eukaryotic translation initiation factor 5A-1 – 6.49 1 16.8
Identiﬁed peptides MH+ [Da] RT
AAVAIKAMAK 973.586 16.42
Q15942 Zyxin – 2.62 1 61.2
Identiﬁed peptides MH+ [Da] RT
FTCHQCAQQLQGQQF 1766.776 21.75
Q96AE4 Far upstream element-binding protein 1 [2] 3.11 1 67.5
Identiﬁed peptides MH+ [Da] RT
YYAQTSPQGMPQHPPAPQGQ 2182.995 18.81
Q32P51 Heterogeneous nuclear ribonucleoprotein A1-like 2 5.63 1 34.2
Identiﬁed peptides MH+ [Da] RT
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Table 1 (Continued)
Accessiona,b Descriptiona Identiﬁcation in
medulloblastoma
cell lines
S
Coverage
#
Peptides
MW
[kDa]
NNQSSNFGPMKGGNFGGR 1868.846 19.13
P0C6T2 Dolichyl-diphosphooligosaccharide–protein glycosyltransferase subunit 4 – 100.00 1 4.2
Identiﬁed peptides MH+ [Da] RT
MITDVQLAIFANMLGVSLFLLVVLYHYVAVNNPKKQE 4191.281 48.30
P63313 Thymosin beta-10 – 97.73 3 5.0
Identiﬁed peptides MH+ [Da] RT
A(Acetyl)DKPDMGEIASFDKAKLKKTETQEKNTLPTKETIEQEKRSEIS 4934.537 20.90
A(Acetyl)DKPDMGEIASFDKAKLKKTETQEKNTLPTKETIEQEKRSE 4734.412 20.49
LKKTETQEKNTLPTKETIEQEKRSEIS 3188.704 17.17
P62328 Thymosin beta-4 – 97.73 4 5.0
Identiﬁed peptides MH+ [Da] RT
S(Acetyl)DKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES 4961.501 19.82
S(Acetyl)DKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAG 4745.421 19.89
LKKTETQEKNPLPSKETIEQEKQAGES 3070.588 16.77
TETQEKNPLPSKETIEQEKQAGES 2701.320 17.56
P31949 Protein S100-A11 – 99.05 4 11.7
Identiﬁed peptides MH+ [Da] RT
A(Acetyl)KISSPTETERCIESLIAVFQKYAGKDGYNYTLSKTEFLSFMNTELAAFTKNQ
KDPGVLDRMMKKLDTNSDGQLDFSEFLNLIGGLAMACHDSFLKAVPSQKRT
11644.768 39.15
IAVFQKYAGKDGYNYTLSKTEF 2543.280 24.27
IGGLAMACHDSF 1221.537 24.27
IGGLAMACHDSFLKAVPSQKRT 2330.211 23.37
P40926 Malate dehydrogenase, mitochondrial [2] 13.91 3 35.5
Identiﬁed peptides MH+ [Da] RT
AKVAVLGASGGIGQPLSL 1637.958 26.18
AKVAVLGASGGIGQPLSLLLKNSPLVSRLTL 3072.844 33.89
SLVDAMNGKEGVVECS 1637.750 22.24
P30041 Peroxiredoxin-6 [2] 29.02 2 25.0
Identiﬁed peptides MH+ [Da] RT
PGGLLLGDVAPNFEANTTVGRIRFHDFLGDSWGIL 3754.940 34.03
PGGLLLGDVAPNFEANTTVGRIRFHDFLGDS 3285.675 30.01
P60468 Protein transport protein Sec61 subunit beta – 25.00 1 10.0
Identiﬁed peptides MH+ [Da] RT
PGPTPSGTNVGSSGRSPSKAVAAR 2238.157 15.56
P63279 SUMO-conjugating enzyme UBC9 – 24.68 1 18.0
Identiﬁed peptides MH+ [Da] RT
LNEPNIQDPAQAEAYTIYCQNRVEYEKRVRAQAKKFAPS 4539.288 24.68
P62263 40S ribosomal protein S14 – 21.85 1 16.3
Identiﬁed peptides MH+ [Da] RT
APRKGKEKKEEQVISLGPQVAEGENVFGVCHIF 3623.902 28.23
P08670 Vimentin [2], [6], [3] 13.30 16 53.6
Identiﬁed peptides MH+ [Da] RT
DGQVINETSQHHDDLE 1836.799 17.08
IKTVETRDGQVINETSQHHDDLE 2664.284 17.76
LIKTVETRDGQVINETSQHHDDLE 2777.369 18.89
MFGGPGTASRPSS 1251.579 17.39
NLRETNLDSLPLVDTHSKR 2208.170 21.82
NLRETNLDSLPLVDTHSKRTLLIK 2776.567 23.88
NLRETNLDSLPLVDTHSKRTLLIKTVETRDGQVINETSQHHDDLE 5180.648 23.97
RETNLDSLPLVDTHSKR 1981.045 20.19
RETNLDSLPLVDTHSKRTLLIK 2549.439 22.98
RETNLDSLPLVDTHSKRTLLIKTVETR 3135.735 23.09
RETNLDSLPLVDTHSKRTLLIKTVETRDGQVINETSQHHDDLE 4953.527 23.49
RRMFGGPGTASRPSSSR 1806.913 14.46
TLLIKTVETR 1173.721 19.85
TLLIKTVETRDGQVINETSQHHDDLE 2991.500 22.31
TVETRDGQVINETSQHHDD 2180.981 15.67
TVETRDGQVINETSQHHDDLE 2423.109 17.64
P04406 Glyceraldehyde-3-phosphate dehydrogenase [5], [6]c, [7]d, [8] 19.40 6 36.0
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Table 1 (Continued)
Accessiona,b Descriptiona Identiﬁcation in
medulloblastoma
cell lines
S
Coverage
#
Peptides
MW
[kDa]
Identiﬁed peptides MH+ [Da] RT
FQYDSTHGKFHGTVKAENGKLVINGNPITIFQERDPSKIKWGDAGAEY 5363.670 25.49
ISWYDNEFGYSNRVVD 1963.882 25.69
ISWYDNEFGYSNRVVDL 2076.966 28.30
QERDPSKIKWGDAGAEY 1949.935 19.94
YDNEFGYSNRVVD 1577.690 20.67
YDNEFGYSNRVVDL 1690.768 24.70
P84243 Histone H3.3 – 40.53 2 15.3
Identiﬁed peptides MH+ [Da] RT
RFQSAAIGALQEASEAYL 1924.978 28.17
FEDTNLCAIHAKRVTIMPKDIQLARRIRGERA 1109.574 23.10
P67809 Nuclease-sensitive element-binding protein 1 [6]c 10.80 1 35.9
Identiﬁed peptides MH+ [Da] RT
RRPENPKPQDGKETKAADPPAENSSAPEAEQGGAE 3658.746 15.04
P06748 Nucleophosmin [6]c 9.18 1 32.6
Identiﬁed peptides MH+ [Da] RT
SIRDTPAKNAQKSNQNGKDSKPSSTPR 2912.505 6.13
Q13263 Transcription intermediary factor 1-beta [2] 1.32 1 88.5
Identiﬁed peptides MH+ [Da] RT
SGEGEVSGLMR 1121.526 19.12
P43243 Matrin-3 [2] 5.43 2 94.6
Identiﬁed peptides MH+ [Da] RT
DSQGHGRDLSAAGIGLLAAATQSLSMPASLGR 3108.579 30.85
GNLGAGNGNLQGPR 1324.672 16.61
O43390 Heterogeneous nuclear ribonucleoprotein R [2] 1.58 1 70.9
Identiﬁed peptides MH+ [Da] RT
YQDTYGQQWK 1316.596 16.71
P22626 Heterogeneous nuclear ribonucleoproteins A2/B1 [2] 17.85 5 37.4
Identiﬁed peptides MH+ [Da] RT
GGPYGGGNYGPGGSGGSGGYGGR 1944.825 17.57
NMGGPYGGGNYGPGGSGGSGGYGGR 2189.906 19.01
GGGNYGPGGSGGSGGYGGR 1570.664 15.17
GGGPGGGNFGGSPGYGGGR 1564.687 17.52
NQQPSNYGPMKSGNFGGSR 2025.920 18.09
P04908 Histone H2A type 1-B/E – 82.31 2 14.1
Identiﬁed peptides MH+ [Da] RT
VLLPKKTESHHKAKGK 1801.083 4.75
ILELAGNAARDNKKTRIIPRHLQLAIRNDEELNKLLGKVTIAQGGVLPNIQA 5696.263 27.39
P06454 Thymosin alpha-11 – 100.00 1 3.8
Identiﬁed peptides MH+ [Da] RT
S(Acetyl)DAAVDTSSEITTKDLKEKKEVVEEAENGRDAPAN 3788.834 21.32
S4R457 Heterogeneous nuclear ribonucleoprotein K [5], [9] 48.05 1 8.8
Identiﬁed peptides MH+ [Da] RT
ETEQPEETFPNTETNGEFGKRPAEDMEEEQAFKRSE 4087.810 23.10
P06454-2 Prothymosin alpha isoform 2 – 99.09 1 12.0
Identiﬁed peptides MH+ [Da] RT
S(Acetyl)DAAVDTSSEITTKDLKEKKEVVEEAENGRDAPANGNANEENGEQEADNEVDEEEEEGGEEEEEEEEGD
GEEEDGDEDEEAESATGKRAAEDDEDDDVDTKKQKTDEDD
11978.902 21.64
Q15056 Eukaryotic translation initiation factor 4H – 13.30 1 27.4
Identiﬁed peptides MH+ [Da] RT
TVATPLNQVANPNSAIFGGARPREEVVQKEQE 3449.776 23.82
P0CG48
P0CG47
Ubiquitin (1–76) – 97.23 1 8.5
Identiﬁed peptides MH+ [Da] RT
MQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGG 8560.638 30.42
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Fig. 1. Gene Ontology (GO) classiﬁcation of identiﬁed proteins in DAOY
medulloblastoma cells.
Table 1 (Continued)
Accessiona,b Descriptiona Identiﬁcation in
medulloblastoma
cell lines
S
Coverage
#
Peptides
MW
[kDa]
Q9UNM1 Chaperonin 10-related protein – 75.26 1 10.3
Identiﬁed peptides MH+ [Da] RT
VERSAAETVTKGGIMLPEKSQGKVLQATVVAVGSGSKGKGGEIQPVSVKVGDKVLLPEYGGTKWLDDKDYFL 7557.081 26.46 a
a Bold letters (accession n. and sequences) refer to proteins and peptide fragments identiﬁed in DAOY cells culture in serum-free medium after 24, 48 and 72 h.
b Underlined accessions refer to proteins not previously identiﬁed in DAOY cells.
c Medullospheres.
d Medulloblastoma cell exosomes.
C. Martelli et al. / EuPA Open Proteomics 12 (2016) 13–21 19fragment mass “false”, maximum retention time difference
0.5 min. Unspeciﬁc enzyme was set. Minimum and maximum
peptide length was 5 and 144 residues, respectively, and peptide
conﬁdence was set to “high”. Dynamic methionine oxidation
(+15.99 Da) was set. Protein and peptide spectra matches were
validated by using the Target Decoy PSM Validator that estimates
the number of false positive identiﬁcations among all those found.
The strict target false discovery rate (FDR) value was set to 0.01,
while the relaxed FDR value was set to 0.05.
2.6. Functional clustering, Protein Classiﬁcation and Protein-Protein
Interaction analyses
All detected proteins were classiﬁed according to the Gene
Ontology (GO) annotations, regarding molecular function, biologi-
cally process, and cellular component. Dataset processing was
performed by the Protein ANalysis THrough Evolutionary Relation-
ships (PANTHER) Classiﬁcation System (version 9.0, http://www.
pantherdb.org).
In order to determine the functional relationships among
proteins, the Search Tool for the Retrieval of Interacting Genes/
Proteins (STRING) database of physical and functional interactions
(version 10) was used employing the highest conﬁdence (score
0.900) [10].
3. Results and discussion
DAOY cell lysates in acidic solution have been analyzed by
HPLC-ESI-Orbitrap Elite-MS, in order to characterize the intact
proteome by a top-down proteomic strategy. Table 1 lists the
proteins and peptides identiﬁed in cell lysates after 24 h of
starvation in serum-free medium. The corresponding Uniprot
accession number, protein name, sequence coverage, and molecu-
lar mass data, along with the number and the amino acid sequence
of the fragment peptides is included for each identiﬁed protein.
Protein and peptide identiﬁcation was accomplished by both
software elaboration and manual inspection of MS/MS data (see
materials and methods section for details).
Tandem MS software-based data analysis allowed identifying
47 proteins, most of them being disclosed through the characteri-
zation of peptide fragments. For some proteins, the number (n) of
fragment peptides detected was high, in particular, for vimentin
(MW 53.6 kDa, n = 16), peptidyl-prolyl cis-trans isomerase A (MW
18.0 kDa, n = 8), glyceraldehyde-3-phosphate-dehydrogenase (MW
36.0 kDa) and proﬁlin-1 (MW 15.0 KDa) (both n = 6), heteroge-
neous nuclear ribonucleoprotein A2/B1 (MW 37.4 kDa, n = 5),
elongation factor 1-alpha 1 (MW 50.1, n = 4), S100A11 (MW
11.7 kDa, n = 4) and thymosin beta-4 (MW 5.0 kDa, n = 3).
Given that sample treatment included a protease inhibitor
cocktail, it may be reasonably assumed that these fragment
peptides are either produced in vivo from parent proteins, with
potential speciﬁc biological functions, or are released as a result of
an extensive protease activity of DAOY cells. Few proteins, namely,
Fig. 2. Biological interaction network of proteins identiﬁed in DAOY cells. Figure produced by use of action view “Interacting” of STRING tool.
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subunit 4, thymosin beta-10 and beta-4, thymosin alpha-11,
protein S100-A11, prothymosin alpha isoform 2, and ubiquitin,
have been characterized entirely or with high sequence coverage.
The manual inspection and annotation of MS2 spectra identiﬁed
6 additional proteins and peptides. These included acetylated
forms and isoforms: the isoform 2 of prothymosin alpha and its
biologically active fragment 2–37 thymosin alpha-11, both N-
terminal acetylated; the heterogeneous nuclear ribonucleoprotein
K; the eukaryotic translation initiation factor 4H; the ubiquitin and
the chaperonin 10-related protein. All the alpha- and beta-
thymosins identiﬁed, listed in Table 1, along with the
S100A11 protein, were N-terminally acetylated after
Met1 removal. The isoform 2 of prothymosin alpha differs from
isoform 1 in missing one glutamic acid residue (des-E40).Table 2
List of the protein identiﬁed both in DAOY cells and medulloblastoma tumor tissue
pool [11].
Accessiona Description
P06454 Thymosin alpha 11
P0CG48 Polyubiquitin-C
P06454-2 Prothymosin alpha isoform 2
P04908 Histone H2A type 1-B/E
P63313 Thymosin beta-10
P62328 Thymosin beta-4
P06733 Alpha-enolase
P62158 Calmodulin
P10809 60 kDa heat shock protein, mitochondrial
Q9BQE3 Tubulin alpha-1C chain
P40926 Malate dehydrogenase, mitochondrial
P62937 Peptidyl-prolyl cis-trans isomerase A
P60709 Actin, cytoplasmic 1
P60174 Triosephosphate isomerase
P22626 Heterogeneous nuclear ribonucleoproteins A2/B1
P04406 Glyceraldehyde-3-phosphate dehydrogenase
a Bold accessions refer to proteins identiﬁed also in medulloblastoma classic
histotype [14].It is noteworthy that 25 proteins (underlined accessions in
Table 1) identiﬁed in this study have, to the best of our knowledge,
never been described in previous proteomic studies of DAOY cells.
The GO classiﬁcations of the identiﬁed proteins based on
cellular component, molecular function and biological processes,
are reported in Fig. 1. The majority of them are components of
organelles (35%), cell parts (38%) and macromolecular complexes
(19%), and are mainly involved in binding (41%), catalytic (23%) and
structural (20%) activities. Metabolic and cellular processes were
the most prevalent annotations (see Fig. 1). In addition, the
connections and functional interactions between the protein
entries listed in Table 1, have been evaluated by the STRING
search tool (Fig. 2). With the exception of calreticulin (CALR),
thymosin b10 (TMSB10), zyxin (ZYX), dolichyl-diphosphooligo-
saccharide-protein glycosyltransferase subunit 4 (OST4), and
nuclear ubiquitous casein and cyclin-dependent kinase substrate
1 (NUCKS1), all the identiﬁed proteins appeared functionally
interconnected, mainly through binding interactions.
The identiﬁcation of alpha- and beta-thymosins in DAOY cells is
particularly noteworthy. We have previously demonstrated the
presence of this family of proteins and peptides in medulloblasto-
ma tissues [11], and postulated a possible role as biomarkers of
tumor aggressiveness. In particular, the overexpression of thymo-
sin beta-4 and the exclusive presence of thymosin beta-10 and of
alpha-thymosins, (including thymosin alpha-11) speciﬁed the
malignant medulloblastoma tissue from the low grade pilocytic
astrocytoma [11]. The ﬁnding of thymosin alpha-11 and thymosin
beta-10 in the DAOY cell line could, therefore, conﬁrm the
importance of these peptides in characterizing the aggressiveness
and high malignancy of this tumor.
Other proteins and peptides identiﬁed in DAOY cells have been
previously characterized also in medulloblastoma tumor tissues
[11–14]. Coﬁlin-1 and 60 kDa heat shock mitochondrial protein
have been identiﬁed in anaplastic medulloblastoma, whereas the
heterogeneous nuclear ribonucleoprotein k and calmodulin were
found expressed in the classic and desmoplastic/nodular subtypes,
respectively [12]. In particular, the heterogeneous nuclear
C. Martelli et al. / EuPA Open Proteomics 12 (2016) 13–21 21ribonucleoproteins resulted altered in MYC-ampliﬁed medullo-
blastoma tumors belonging to the molecular subgroup 3 [13]. The
resulting alteration of the glycolytic metabolism may possibly
explain the tumor aggressiveness and cell viability. Table 2 lists the
species identiﬁed in medulloblastoma tissue pool by top-down
proteomic approach in our previous paper [11]. Some of these
proteins (accession in bold) have been also characterized in classic
medulloblastoma histotype by 2DE-MALDI/TOF analysis [14].
The full list of proteins identiﬁed in DAOY cells (Table 1) were
explored in DAOY cells cultured under the same experimental
conditions and different time of starvation, namely 48 and 72 h.
Out of the 53 proteins identiﬁed at 24 h, 37 were stably expressed
in DAOY cells over time (displayed in Table 1 as bold-case accession
number). The proteins were further characterized based on their
peptide fragments, most of which were reproducibly detected at all
time points after starvation (peptides in bold, Table 1). In
particular, beta-thymosins and S100A11 retained the N-terminal
acetylation PTM over the time course. As far as alpha-thymosins
are concerned, only the alpha-11 peptide was conserved, whereas
its parent protein, namely the prothymosin alpha isoform 2, was
undetectable at 48 and 72 h.
These proteins, and particularly, their fragment peptides, were
not inﬂuenced by culture time, indicating that they are associated
with DAOY cells, regardless of starvation. These proteins/protein
fragments could represent interesting clues for testing conditions/
drugs able to perturb tumor growth using the DAOY cells as model.
4. Conclusions
Top-down proteomic analysis of a DAOY medulloblastoma cell
line provides a new approach for unraveling the multifaceted
features of the proteome of brain tumors, by both conﬁrming
previous ﬁndings and generating new information. Unlike the
bottom-up approach, the top-down strategy has the advantage of
being able to characterize intact proteins and peptides with their
PTMs and proteoforms. The naturally occurring peptide fragments
require further investigations, to clarify their correlation to the
corresponding parent proteins and to functionally validate their
biological functions. In this study, the presence of protein
fragments may be the result of the activity of intracellular
proteases, part of the so-called cancer “degradome” [15]. These
may be either speciﬁc, i.e. functionally signiﬁcant, or aspeciﬁc
peptides.
Although some of the identiﬁed proteins have already been
described in DAOY cells, the characterization of their naturally
occurring fragment peptidome was not reported before. Our data,
therefore, provide original hints towards the complete characteri-
zation of medulloblastoma molecular features.
The proﬁling of tumor cell cultures proteome/peptidome
represents a valid tool to characterize tumors at molecular level
and to support whole tissue studies. In particular, our data
illustrate that top-down proteomic analysis is essential to
distinguish protein isoforms, PTMs, naturally occurring biological-
ly active peptides and protein fragments, which may all be crucial
in tumor etiopathogenesis.Conﬂict of interest
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